NIK-SMI1

Inhibitor of MAP3K14

Structure

SERP Rating

In Cells

(2 ratings)

In Model Organisms

(2 ratings)

note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars.

Probe NIK-SMI1 is in the process of SERP review.

Please continue to check back for new reviews and commentary.

Information

MAP3K14

Inhibitor

~~100 nM~~
Reviewer recommended concentration: 150-400 nM

Probe Availability:

In Vitro Validations

Uniprot ID: Q99558

Target Class: Kinase

Target SubClass: STE

Potency: Ki

Potency Value: 0.23 ± 0.17 nM

Potency Assay: NIK Ki biochemical assay

PDB ID for probe-target interaction (3D structure): --

Structure-activity relationship: yes

Target aliases:

Mitogen-activated protein kinase kinase kinase 14, ...

DOI Reference: 10.1021/acs.jmedchem.8b00678

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Probe Selectivity in Vitro:

RelB 70 nM, RelA no inhibition, KHS1 > 50% in a 228 panel of kinases tested at 0.100 μM

Probe Selectivity in Cell:

Outside target family - Indirect: no inhibition of nuclear translocation of RelA

I have extra information to add

SERP ratings and comments

SERP Ratings

In Cell Rating

In Model Organisms

SERP Comments:

NIK SMI1:

Is a highly potent and selective NF-κB-inducing kinase (NIK) inhibitor with Ki of 0.23 nM for NIK-catalyzed hydrolysis of ATP to ADP.
Inhibits expression of NF-κB response element regulated firefly luciferase reporter gene in HEK293 cells at an IC50 of 34 nM.
has a favorable pharmacokinetic profile across species.
Inhibits BAFF-induced B cell survival in vitro (close to phenotype assay) at an IC50 of 373 nM.
Inhibits BAFF signalling and reduces splenic marginal zone B cells in mice at doses from 60-200 mg/kg.

(last updated: 8 Dec 2020 )

SERP Ratings

In Cell Rating

In Model Organisms

SERP Comments:

The primary references provide strong support for on target NIK (MAP3K14) potency, efficacy and selectivity within the kinome for NIK SM1. In functional assays ~1 uM in cells and 200 mg/kg BID orally in C57BL/6 mice are recommended based on the data in the provided references. Selectivity profiling outside the kinome for safety pharmacology is not available and this unknown should modulate interpretation of in vivo results if readouts differ from the systems investigated in the references.

(last updated: 2 Mar 2021 )